Phase I Trial Of Intravenous Peptide-Pulsed Dendritic Cells in Patients With Metastatic Melanoma

Journal of Immunotherapy

Volumn 24, Issue 1, 2001, Pages 66-78

  Lau, Roy ^a   Wang, Flora ^a   Jeffery, Georgia ^a   Marty, Verna ^a   Kuniyoshi, Jon ^a   Bade, Elizabeth ^a   Ryback, Mary Ellen ^a   Weber, Jeffrey ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Dendritic cell; Immune response; Melanoma; Peptide; Serumless media

Indexed keywords

CD14 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONOPHENOL MONOOXYGENASE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; AGED; CELL DIVISION; DEMOGRAPHY; DENDRITIC CELLS; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PHENOTYPE; SKIN TESTS; SURVIVAL RATE;

EID: 0035141784     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200101000-00008     Document Type: Article

References (65)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
2. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9 (1):10-6.
3. Lotze MT. Not just an antigen-presenting cell: 5th international symposium on dendritic cells in fundamental and clinical immunology. J Leuk Biol 1999; 66:195-200.
4. Sallustro F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 1994; 179:1109-18.
5. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93.
6. O'Doherty U, Steinman RM, Peng M, et al. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J Exp Med 1993; 178:1067-76.
7. Goldman SA, Baker E, Weyant RJ, Clarke MR, Myers JN, Lotze MT. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 1998; 124:641-46.
8. Ambe K, Mori M, Enjoji M. S100 protein positive dendritic cells in colorectal adenocarcinomas: distribution and relation to the clinical prognosis. Cancer 1989; 63:496-515.
9. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 co-stimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183:87-97.
10. Paglia P, Chiodoni C, Rodolfo M, et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183:317-22.
11. Ossevoort MA, Feltkamp MCW, van Keen KJH, et al. Dendritic cells as carriers for a cytotoxic T lymphocyte epitope based peptide vaccine against a human papillomavirus type-16 induced tumor. J Immunother 1995; 18:86-94.
12. Porgador A, Snyder D, Gilboa E. Bone marrow-derived dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995; 182:255-260.
13. Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994; 24:605-10.
14. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen specific, CTL mediated protective tumor immunity. J Exp Med 1996; 183:283-87.
15. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52-8.
16. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-332.
17. Thurner B, Haendle I, Roder C, et al. Vaccination with MAGE-3Al peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytolytic T-cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190:1669-78.
18. Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA0A0201 specific peptides from prostate specific membrane antigen. Prostate 1996; 29:371-80.
19. Kundig TM, Althage A, Hengartner H, Zinkernagel RM. Skin test to assess viral specific cytotoxic T cell activity. Proc Natl Acad Sci USA 1992; 89:7757-61.
20. Puccetti P, Bianchi R, Fioretti M, et al. Use of a skin test assay to determine tumor specific CD8+ T cell reactivity. Eur J Immunol 1994; 24:1446-52.
21. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999; 5:2756-65.
22. Caux C, Vanbervliet B, Massacrier C, et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on dendritic cells. J Exp Med 1994; 180:1841-48.
23. Larsen CP, Ritchie SC, Pearson TC, et al. Functional expression of the co-stimulatory molecule B7/BB1 on murine dendritic cell populations. J Exp Med 1992; 176:1215-23.
24. Zhou L-J, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 1995; 154:3821-35.
25. Steinman RM, Witmer MD. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte response in mice. Proc Natl Acad Sci USA 1978; 75:5132-36.
26. Inaba K, Metlay JP, Crowley MT, et al. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 1990; 172:631-40.
27. Inaba K, Young JW, Steinman RM. Direct activation of CD8+ cytolytic T lymphocytes by dendritic cells. J Exp Med 1987; 166:182-94.
28. Sallusto F, Palermo B, Lenig D, et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999; 29:1617-25.
29. Tuting T, Wilson CC, Martin DM, et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol 1998; 160:1139-47.
30. Tjandrawan T, Martin DM, Maeurer MJ, et al. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immuno 1998; 21:149-57.
31. Romani N, Reider DH, Ebner MS, et al. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J Immunol Method 1996; 196:137-49.
32. Caux C, Vanbervliet B, Massacrier C, et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha. J Exp Med 1996; 184:695-704.
33. Caux C, Massacrier C, Vanbervliet B, et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 1997; 90:1458-70.
34. Kuniyoshi JK, Kuniyoshi CJ, Lim AM, et al. Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T-cells. Cell Immunol 1999; 193:48-58.
35. Mortarini R, Anichini A, Di Nicola S, et al. Autologous dendriticc ells derived from CD34+ progenitors and from monocytes are not functionallt equivalent antigen-presenting cells in the induction of MART-1 27-35 specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 1997; 57:5334-40.
36. Ferlazzo G, Wesa A, Wei-Zen W, et al. Dendriticc ells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells. J Immunol 1999; 163:3597-3604.
37. Morse MA, Coleman RE, Akabani G, et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59:56-62.
38. Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999; 104:173-80.
39. Adema GJ, DeBoer AJ, Vogel AM, et al. Molecular characterization of the melanocyte lineage specific antigen gp100. J Biol Chem 1994; 269:20126-133.
40. Bakker ABH, Schreurs WJ, de Boer AJ, et al. Melanocyte lineage specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179:1005-11.
41. Kawakami Y, Eliyahu S, Delgado C, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91:6458-62.
42. Bakker ABH, Schreurs MWJ, Tafazzul G, et al. Identification of a novel peptide derived from the melanocyte specific gp 100 antigen as the dominant epitope recognized by an HLA-A2.1 restricted anti-melanoma CTL line. Int J Cancer 1995; 62:97-102.
43. Skipper JC, Kittlesen DJ, Hendrickson RC, et al. Shared epitopes for HLA-A3 restricted melanoma-reactive human cytolytic T lymphocytes include a naturally processed epitope from pMel17/gp100. J Immunol 1996; 157:5027-33.
44. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-27.
45. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene encodes for an antigen recognized autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178:489-95.
46. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994; 24:759-64.
47. Skipper JCA, Hendrickson RC, Gulden PH, et al. An HLA-A2 restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel processing pathway for membrane proteins. J Exp Med 1996; 183:527-34.
48. Kawakami Y, Eliyahu S, Delgado C, et al. Cloning of the gene coding for a shared melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 96:3515-19.
49. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180:35-42.
50. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52.
51. Romero P, Gervois N, Schneider J, et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997; 159:2366-74.
52. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995; 154:2257-65.
53. Hunt DF, Henderson RA, Shabanowitz J, et al. Characterization of peptides bound to the class I molecule HLA-A2.1 by mass spectrometry. Science 1992; 255:1261-64.
54. Storkus WJ, Zeh HJ, Maeurer MJ, et al. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating lymphocytes. J Immunol 1993; 151:3719-26.
55. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264:716-19.
56. Loftus DJ, Castelli C, Clay TM, et al. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med 1996; 184:647-57.
57. Kuribayashi K, Tsukiyama M, Takenaka T. Secretion patterns of Th1-and Th2-type cytokines in immune deviation caused by dendritic cells. Arch Aller Immunol 1997; 114:30-36.
58. Ahuja SS, Reddick RL, Sato N, et al. Dendritic cell (DC) based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol 1999; 163:3890-97.
59. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180:1263-72.
60. Cella M, Scheidegger D, Palmer Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184:747-52.
61. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ helper and a T-killer cell. Nature 1998; 393:474-77.
62. Bennett SRM, Carbone FR, Karamalis F, et al. Help for cytotoxic T-cell responses is mediated by CD40 signaling. Nature 1998; 393:478-80.
63. Schoenberger SP, Toes REM, van der Voort EIH, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393:480-83.
64. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of mature and immature dendritic cells by distinct chemokines expressed at different anatomic sites. J Exp Med 1998; 188:373-86.
65. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cell specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5:677-85.